The company develops biological drugs, including antibodies, to increase response rates in immuno-oncology. Genagon's platform identifies pathways in immune cells, discovers cancer's mechanisms to inhibit the innate immune system, and offers treatments for oncology and inflammatory diseases. The company's research originates from Uppsala University and Karolinska Institutet, providing the healthcare sector with new discoveries of unstudied proteins. Genagon is currently in the seed stage of development.